Hologic stock holds close to 52-week high as investors digest January earnings
Published on 08/25/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hologic, Inc. (ISIN US4364401012) stock is trading in the mid-$70 range as of August 24, 2026, leaving the shares close to a 52-week high of $76.07 and giving the medical technology company a market value of $16.97 billion.
Per recent market data as of August 24, 2026, the Hologic share price stands around $76.07 within a 52-week range of $51.90 to $76.07, highlighting a strong recovery over the past year and a valuation based on a trailing price-to-earnings ratio of 31.67.
For investors, that combination of a high single-day price level alongside a double-digit net margin and a forward P/E multiple of 17.76 underlines a stock that the market currently values as a profitable, moderately growing healthcare equipment provider.
Latest earnings and margin profile
According to the latest quarterly overview for Hologic, the company released earnings data on January 29, 2026, covering its most recent reported quarter within the current fiscal year that ends on September 30, 2026.
In that January 29, 2026 quarter, Hologic generated $565.70 million in net income on a trailing twelve-month basis, delivering a net margin of 13.18 percent and trailing twelve-month earnings per share of $2.40.
The valuation framework in that same overview shows a trailing P/E ratio of 31.67 against a forward P/E ratio of 17.76, implying expectations for EPS expansion relative to trailing earnings as the fiscal 2026 year progresses.
That margin and earnings profile matters because it sets the backdrop for consensus expectations and helps explain why the Hologic stock trades with a market capitalization of $16.97 billion as of August 24, 2026, a level that reflects investors’ willingness to pay a mid-teens forward multiple for a mid-teens margin business.
Consensus view and price targets
The same analyst aggregation shows that Hologic currently carries a consensus rating of Hold, with 12 analysts contributing to the coverage and assigning an average price target of $79.13 for the stock.
Within that set of published targets, the high price target is $90.00, the low stands at $76.00, and the current share price of roughly $76.07 as of August 24, 2026 therefore sits only modestly below the average target and effectively matches the low end of the formal range.
Putting those numbers together, the implied potential upside from the current quote to the average target is 4.1 percent, while the difference between the present price and the 52-week high of $76.07 is minimal, underscoring that Hologic stock is already trading close to levels previously seen over the past year.
For investors evaluating whether to add or trim exposure, the small gap between current price and consensus target, combined with the Hold stance, points toward a view that much of the fundamental story is already reflected in the share price, even if earnings growth could still justify the forward multiple of 17.76.
Business profile and Breast Health focus
Hologic, Inc. is a medical technology company with a focus on women’s health, operating across diagnostic imaging, molecular diagnostics, and surgical solutions, with breast health forming a core franchise.
In practical terms, that means Hologic sells breast imaging systems, biopsy devices, and related technology used by hospitals and screening centers to detect and manage breast cancer, as well as offering molecular assays and instruments used for gynecologic and sexually transmitted infection testing.
While the latest January 29, 2026 quarter figures are presented at a consolidated level in the available overview rather than broken out by segment, the company’s emphasis on breast health and diagnostics means that demand trends in screening programs and procedural volumes directly influence revenue and margin performance in upcoming quarters.
Historically, the company has highlighted its role in expanding access to high-quality breast imaging, and investors often watch procedure counts and capital equipment replacement cycles for clues on how strongly the breast health division may contribute to future earnings.
Representative product in imaging
One representative product in Hologic’s portfolio is its 3D mammography system, a digital breast tomosynthesis platform designed to provide high-resolution, layered images that can improve the detection of small lesions compared with conventional 2D mammography.
These systems are used in routine screening and diagnostic follow-up, giving radiologists clearer visualization of breast tissue and potentially reducing callbacks and unnecessary biopsies, which can be important both for patient experience and for healthcare system efficiency.
For Hologic, each installed 3D mammography system not only generates capital equipment revenue but also contributes to ongoing service and consumable sales, creating a recurring revenue stream that can support the company’s mid-teens net margin profile.
Hologic stock valuation and trading context
As of August 24, 2026, Hologic stock trades on the Nasdaq exchange under the symbol HOLX, at a price close to $76.07 within a 52-week range of $51.90 to $76.07, with a market capitalization of $16.97 billion based on those figures.
Measured against the trailing twelve-month EPS of $2.40, that quote implies a trailing P/E ratio of 31.67, while the forward P/E ratio of 17.76 reflects expectations for earnings growth as fiscal 2026 unfolds.
For investors, the key numerical comparison is that the current price sits just below both the 52-week high and the average price target of $79.13, suggesting limited near-term upside on valuation alone but leaving room for the stock to track higher if Hologic can deliver stronger-than-expected results in its next quarterly report.
Read more
Further details on Hologic’s business, governance, and investor relations materials are available on the company’s official website.
Fact box
Company: Hologic, Inc.
ISIN: US4364401012
Ticker: HOLX
Exchange: Nasdaq
Price (as of August 24, 2026, 4:00 p.m. ET): $76.07 USD
Market cap: $16.97 billion (as of August 24, 2026)
Sector / Industry: Healthcare - Healthcare Equipment & Supplies
Index membership: S&P 500
